Oligonucleotide therapies— nucleic acid polymers with the potential to treat or manage a wide range of diseases— are experiencing tremendous growth in the pharmaceutical industry. But, performing the needed PK/PD and clinical pharmacology assessments to optimize the safety and efficacy of investigational oligonucleotide candidates and gain regulatory approval can be challenging.
It’s enough to make you say, “siRNA, miRNA or antisense oligos, oh my!”
In this webinar, our panel of oligonucleotide drug development experts discussed the latest trends and best practices in this field.
